32. Reblozyl

Bristol-Myers Squibb
(Bristol-Myers Squibb)

Active ingredient: luspatercept–aamt 
Disease: anemia in patients with beta thalassemia 
Peak sales estimate: $2 billion 
Approved: Nov. 8, 2019
Companies: Bristol-Myers Squibb (Celgene) and Acceleron 

The scoop: During its last days as an independent company, Celgene saw Reblozyl win approval for anemia linked to beta thalassemia, a blood disorder that is treated with red blood cell transfusions. Although transfusions are a lifesaving treatment, they can eventually lead to iron overload that can cause organ failure and shorten a patient’s lifespan. It is the first drug for this type of anemia, but Bristol-Myers Squibb and Acceleron aren’t stopping there. The duo is also seeking approval in myelodysplastic syndromes, a group of cancers in which immature blood cells in the bone marrow don’t fully develop and become healthy blood cells. They are also treated with transfusions. If Reblozyl nabs a second nod, analysts figure it could hit $2 billion in yearly sales. — Amirah Al Idrus 

32. Reblozyl

Suggested Articles

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.

By redeploying staff, the FDA thinks it can respond to COVID-19-related requests and review protocols within 24 hours of receipt.

The partners leveraged their proximity to the initial outbreak and experience with SARS and MERS to build up a library of neutralizing antibodies.